ArticleBMB reports2014

MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN.

Xingming Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.